I Peace

Koji Tanabe, Ph.D., CEO
Palo Alto, CA
I Peace’s proprietary manufacturing platform enables the fully-automated mass production of discrete iPSCs from multiple donors in a single room. Increasing the available number of clinical-grade iPSC lines allows our customers to take differentiation propensity into account to select the most appropriate iPSC line for their clinical research at significantly reduced cost. Our goal is to create iPSCs for every individual that become his/her stem cell for life. We have built a GMP facility authorized by the PMDA (Japanese FDA equivalent) that is capable of full automation to generate iPSCs on a mass scale to dramatically reduce cost.

By using this website you agree to accept our Privacy Policy and Terms & Conditions